ABSTRACT
Most platelet transfusions in large academic medical centers are observed in blood and marrow transplant patients and hematology/oncology patients receiving chemotherapy. Another common use of platelet transfusion is in thrombocytopenic patients or in patients receiving antiplatelet drugs undergoing invasive procedures such as lumbar puncture, paracentesis, thoracentesis, colonoscopy, endoscopy, and central line placement or removal. Although platelet transfusion in actively bleeding patients is essential, almost all platelet transfusions are administered prophylactically in this group of patients to either minimize bleeding risk or to correct laboratory values. The goal platelet count for many of these procedures was arbitrarily chosen and is not evidence based. 1, 2 In some of these patients, particularly those with immune destruction of platelets, including liver cirrhosis and hepatitis C, the patients' platelet counts do not increase with platelet infusion or increase only marginally. Nevertheless, in many of the patients receiving prophylactic platelets for procedures, a postplatelet count is usually not done prior to the procedure, and there are no laboratory tests predictive of hemorrhage. [3] [4] [5] This use of platelet transfusion in these settings has no evidence base except expert opinion, and no data exist on key clinical outcomes, including bleeding, thrombosis, organ injury from inflammation, or mortality. Indeed, abundant observational studies suggest that patients undergoing invasive procedures without prophylactic platelet transfusions or who fail to achieve arbitrary platelet count targets rarely bleed. 6, 7 Clinicians have traditionally viewed platelet transfusions as beneficial with few drawbacks. Over the past few decades, new data suggest this is not the case. Numerous complications are associated with platelet and other blood product transfusion such as transfusion-associated lung injury (TRALI), transfusion-associated cardiac overload (TACO), transfusion-associated immune modulation, and infectious diseases. The likely mechanisms for infection and organ injury appear to be diverse, ranging from antibody-induced neutrophil activation and endothelial damage to generalized inflammation and immune dysfunction. Furthermore, several retrospective and case studies have reported an association between platelet transfusion and adverse outcomes in liver transplantation, cardiac surgery, and in patients with cardiac stents. [8] [9] [10] [11] [12] [13] [14] [15] [16] Based on these studies, we hypothesized that prophylactic platelet transfusion prior to invasive procedures may be associated with increased risk of thrombosis and poor outcome. Notably, prophylactic platelet transfusion is common prior to invasive procedures, but the frequency of thrombosis postprocedure has not been characterized in any setting. In this prospective nonrandomized observational study, we characterize for the first time the thrombosis and mortality rate of hospitalized patients receiving prophylactic platelet transfusion prior to an invasive procedure.
Materials and Methods

Study Setting
The study was conducted at Strong Memorial Hospital of the University of Rochester Medical Center (URMC) in Rochester, New York. The URMC includes an 870-bed hospital. This study was conducted with institutional human subjects review board approval.
Data Sources and Sample Population
Patients receiving prophylactic platelet transfusion prior to an invasive procedure at our medical center between January 1, 2015, and February 28, 2016, were included in this prospective nonrandomized observational study. As blood orders for patients in the operating room are not reviewed prior to issue and procedures in the operating room are not typically minor procedures such as line insertion and removal, these patients and procedures were not included as part of this study. Because of the difficulty in ascertaining a control group (thrombocytopenic patients who did not receive platelets prior to an invasive procedure), our goal was to assess the incidence of thrombosis and 30-day mortality in patients who receive prophylactic preprocedure platelet transfusion. The widespread assumption that platelet transfusion provides benefit with little risk has not been previously assessed, and we suggest that establishing the rate of these complications and mortality is a first step. Patient age, sex, underlying medical condition(s), preprocedure and postprocedure platelet counts, type of procedure, number of platelet products transfused, and any complications, including thrombosis, within 7 days and death within 30 days of the preprocedure platelet transfusion were recorded. A 7-day cutoff was chosen for thrombosis after platelet transfusion because platelets have a life span of 7 to 10 days on average and 3 to 5 days posttransfusion. We assumed that a thrombotic event further than 7 days after platelet transfusion would have a less likely causeand-effect relationship as most of the transfused platelets would no longer be circulating. A 30-day time period was selected to examine mortality as this time frame could easily be ascertained and data were available for all patients for this time frame. In addition, platelet transfusion would be unlikely to have any effect on patient survival for a longer time frame. Patient medical records and transfusion service records were reviewed regularly for 30 days after prophylactic platelet transfusion. Cause of death was obtained from patient discharge summaries and death certificates. The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology statement.
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At URMC, all nonemergency transfusion requests are evaluated and efforts are made to restrict them to our hospital-wide approved patient blood management program transfusion guidelines. We also interchangeably transfuse doses of four to five prepooled whole-blood, leukoreduced, ABO identical platelets or similar apheresis-derived platelets. Transfusion guidelines at URMC allow for platelet transfusions in patients with platelet counts less than 50 × 10 9 /L undergoing an invasive procedure with documentation of the invasive procedure, which was the indication most frequently cited on platelet orders in this study. Additional order indications cited were "Other," where the ordering clinician documented the reason and/or explanation for the platelet request. All platelet orders for patients with platelet counts above 50 × 10 9 /L were investigated by a resident physician on the transfusion medicine service as were platelet orders requested under the "Other" category. In some instances, platelets were issued to patients who did not meet the institutional transfusion guidelines. One of the most common reasons for issuing platelets in these cases was the perceived high risk of bleeding indicated by the treating physician.
Statistical Analysis
The primary end points were thrombosis within 7 days of the prophylactic platelet transfusion for an invasive procedure and death within 30 days. The data were analyzed using the Student t test and analysis of variance tests (Statistica, Dell Software, Round Rock, TX). Results with a P value of .05 or less were deemed statistically significant.
Results
A total of 376 prophylactic preprocedure platelet transfusion recipients were identified with a total of 398 platelet transfusions. Patients' characteristics are shown in ❚Table 1❚. Most patients (n = 174, 46%) had underlying hematologic disorders such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and atypical hemolytic uremic syndrome. The second most common underlying condition was liver disease (n = 72, 19%). Most patients (n = 342, 91%) receiving prophylactic preprocedure platelet transfusions had platelet counts less than or equal to 50 × 10 9 /L ❚Figure 1❚. The largest group of patients (n = 101, 27%) had counts of 21 to 30 × 10 9 /L platelets ( Figure 1 ). Most patients (n = 356, 95%) received only one dose of platelets. Eighteen (4.8%) patients received two units of platelets, and two (0.5%) patients received three units of platelets prior to the invasive medical procedure. Only 80 (21%) of the 376 patients had postinfusion platelet counts prior to the invasive procedure. The mean platelet increase for these patients was 32.5 × 10 9 /L, and the range was 1 to 135 × 10 9 /L. None of the patients were experiencing clinically evident bleeding prior to procedures. No patients experienced bleeding during or after the procedure. In addition, no patients were reported to have TRALI or TACO as a side effect of the transfusions in the electronic medical record.
Most of the procedures were performed by interventional radiologists who typically required platelets to be given prior to the procedure(s) based on the platelet count. The most common procedure, which comprised 30%, was line placement (114/376) ❚Figure 2❚. The second most common procedure was "Other," which included various procedures not listed individually that were performed on five or fewer patients, followed by lumbar puncture. The mean preprocedure platelet count for line placement was 29 ± 13 × 10 (n = 2). The rate of thrombosis observed in this study was 5.0%, which is about four times higher than what would be expected in patients with cancer. Although not statistically significant, most thrombotic events occurred in older individuals. The mean age of patients developing thrombotic events was 57 ± 20 years compared with 48 ± 23 years in those not developing thrombosis (P = .09). Sixty deaths occurred within 30 days of the preprocedure prophylactic platelet transfusion for a 30-day death rate of 16.0%. The mean ± SD age of patients dying was significantly older (56 ± 18 years) than that of those surviving (46 ± 23 years, P = .002). The major causes of death within 30 days are shown in ❚Figure 3❚. The most common cause of death (n = 29, 48%) was septic shock/ systemic inflammatory response syndrome. The second most common group for cause of death was acute respiratory failure (n = 7, 12%). The mortality rate was similar across all disease categories and types of procedures. ❚Figure 2❚ Most frequent procedures performed. Thirty percent of patients underwent line placement, 9% had BM biopsy, 20% had other procedures, 6.7% had line removal, 5% had paracentesis procedures, 4% had thoracentesis procedures, 2.5% had EGDs, 2% had TIPS, 9.5% had LPs, 2.5% had bronchoscopies, 3% had organ biopsies, 1.5% had tracheostomies, 1.3% had colonoscopies, 1.5% had NG or PEG tubes placed, and 1.5% had embolizations. BM biopsy, bone marrow biopsy; EDG, esophagogastroduodenoscopy; LP, lumbar puncture; NG/PEG, nasogastric or percutaneous endoscopic gastrostomy tube placement; TIPS, transjugular intrahepatic portosystemic shunt.
Notably, the thrombosis and mortality rates among the adult patients did not vary significantly with procedure, platelet count, or diagnosis (data not shown).
Discussion
These data document that prophylactic preprocedure platelet transfusions are associated with an increased rate of 7-day postprocedure thrombosis (5.0%) and 30-day mortality (16.0%). This rate of thrombosis is 21 times higher than the Centers for Disease Control and Prevention (CDC) reported rate of venous thromboembolism (VTE) (0.24%) in hospitalized patients. 18 The rate of VTE has been estimated to be four-to sixfold higher in people with cancer. 8, 19 Sixty-three percent (12 of 19) of the patients who developed thrombosis within 7 days of preprocedure prophylactic platelet transfusion had leukemia, lymphoma, or a solid tumor as their primary underlying medical condition. In our study, 60 (16.0%) deaths occurred within 30 days of preprocedure platelet transfusion. The fact that the mortality rate was similar for patients with widely disparate clinical disorders and a wide variety of procedures being performed suggests a potential causal relationship between the use of prophylactic platelet transfusions and catastrophic outcomes, at least in part. According to CDC records, in 2010, the in-hospital death rate for all patients was 2%. 20 In addition, the 2008 to 2012 in-hospital mortality rate and 30-day mortality rate for Medicare fee-for service beneficiaries hospitalized for acute myocardial infarction (MI), heart failure (HF), and pneumonia (PNA) are as follows: MI, 8.3% and 14.3%; HF, 4.0% and 11.4%; and PNA, 10.4% and 18.9%, respectively. 21 The 16.0% 30-day mortality rate is in line with the in-hospital and 30-day mortality rates for Medicare patients with acute MI, HF, and PNA. 21 While most of the patients in the present study had life-threatening illnesses, which confounds the cause of death, short-term mortality rates of one in six are concerning for a procedure that has no evidence base for efficacy or safety. Larger randomized controlled trials are needed to address this and determine if transfusion is indeed having an effect on mortality or if the patient population that is receiving transfusion would have a similar rate of mortality regardless of transfusion.
Most patients received only one preprocedure prophylactic platelet transfusion, and most (79%, 296) did not have a postinfusion platelet count performed prior to the procedure. Notably, the mean platelet increase for these patients was 32.5 × 10 9 /L with a range of 1 to 135 × 10 9 /L. Thus, the exact effect of the platelet transfusion on platelet count was unknown in most patients. This was particularly surprising and suggested that the platelet transfusions may not have been essential for the procedure since there was little or no concern for achieving any particular postinfusion platelet count. The patients studied also had a variety of procedures performed, some of which were associated with higher risks of bleeding, complication, and death than others, such as transjugular intrahepatic portosystemic shunt vs line placement or line removal. Nonetheless, the mortality rate across platelet counts, procedures, and underlying disease was consistent. Thus, in this study, a patient having a particular ❚Figure 3❚ The various causes of death for the patients who died within 30 days of preprocedure platelet transfusion are shown. The most common cause of death was septic shock/SIRS. Forty-eight percent of patients died of septic shock/SIRS, 12% of acute respiratory failure, 7% of pneumonia, 7% of multiorgan failure, 7% of cardiogenic shock, 3% of ESRD, and 16% of various other causes. ESRD, end-stage renal disease; SIRS, systemic inflammatory response syndrome.
procedure did not appear to be associated with any of the measured outcomes. To further elucidate any effect of a procedure, a randomized controlled trial would be needed in which patients having certain procedures would be matched with comparable platelet counts and either receive or not receive platelets. The present assessment of clinical outcomes and the rate at which they occur in transfused patients will assist power calculations for potential future controlled clinical trials of alternate approaches such as reduced-dose transfusions, prophylactic vs therapeutic platelet transfusions, and use of alternative hemostatic agents such as antifibrinolytics.
This study has several major limitations. One of the main limitations is that it was a nonrandomized prospective observational study and there was no control group for patients undergoing procedures who had low platelet counts but did not receive preprocedure prophylactic platelet transfusions. Notably, we used the CDC reported rate of VTE in hospitalized patients (0.24%) and reported estimates of increased VTE rates in patients with cancer as the best estimate of what the underlying thrombotic risk might be in our patient population. This may be an underestimate or overestimate of what the true underlying risk of thrombosis is in our study population. In addition, platelet count is not a strong predictor of bleeding risk; rather the patient's bleeding history is the best predictor. Further limitations include that many of the patients had underlying medical conditions such as leukemia, lymphoma, solid tumors, or liver disease that could predispose them to thrombosis and/or death. However, when each of these groups of patients was compared with patients with other underlying conditions, we found that all patients were equally as likely to die within 30 days of receiving preprocedure prophylactic platelet transfusions. Another limitation was that it is not possible to assess what role a platelet transfusion played in the observed mortality rate. In addition, due to the observational nature of our study, we cannot determine the comparison death rate or expected death rate in the absence of prophylactic platelet transfusions. Last, the effects of platelet transfusion on patient length of stay and/or intensive care unit admissions are unknown.
Thus, given these limitations, the association observed between preprocedure prophylactic platelet transfusion and subsequent development of thrombosis and/or death may not be causal. However, the clinical outcome findings in this study are among the first to be reported in this setting and suggest that randomized controlled studies are warranted to investigate these associations. Given the absence of evidence for efficacy and safety of current practices, randomized controlled studies are ethical and urgently needed. These data, despite their limitations, serve to highlight previously unrecognized associations between preprocedure prophylactic platelet transfusion and an increased risk of thrombosis and/or mortality.
In earlier studies, Khorana et al 9 examined the medical records of 15,237 hospitalized patients with cancer who received platelet transfusions between 1995 and 2003 at 60 different medical centers. They found that patients who received platelet transfusions had increased risks of venous and arterial thromboembolism as well as death. de Boer et al 10 performed a retrospective study in which they examined platelet transfusion and outcome in 433 adult patients undergoing first-time orthotopic liver transplant. They found that platelet transfusion was associated with poor patient survival and that increasing platelet transfusions were associated with worse survival in a dose-dependent fashion.
In several small studies, platelet transfusion has also been linked to coronary stent thrombosis. Cornet et al 11 reported that three patients with gastrointestinal (GI) bleeding who received platelet transfusions early in the course following stenting subsequently developed stent occlusion 6 to 17 hours following platelet transfusion. Likewise, Shin and Kang 12 reported a case of a patient with aplastic anemia who received a single platelet transfusion and subsequently developed a late stent thrombosis in a drug-eluting stent. The risks associated with platelet transfusion in coronary artery bypass grafting (CABG) have also been debated in the literature, with several studies showing platelet transfusions to be associated with adverse outcomes. Mangano 13 was the first to report that platelet transfusions were associated with a statistically significant increased risk of death in patients who had CABG regardless of aspirin administration. Several subsequent studies also found that platelet transfusions in cardiac surgery were associated with increased mortality. [14] [15] [16] Notably, several studies showed there was no increased risk of mortality in patients having CABG procedures with platelet transfusion. [22] [23] [24] Thus, it appears that platelet transfusions may be associated, perhaps causally to some extent, with both thrombosis as well as mortality.
Recently, Zakko et al 25 performed a retrospective cohort study of patients receiving antiplatelet medications and presenting with GI bleeding. Using univariate analyses, they found that patients with normal platelet counts who received platelet transfusion had higher rates of cardiovascular events, longer hospital stays, and death compared with controls who did not receive platelet transfusions. 25 Using multivariate analyses, they found that patients receiving platelet transfusions had an increased odds ratio of 5.57 for death compared with controls. 25 Interestingly, the adjusted odds ratio for recurrent bleeding was 1.47 for patients receiving platelet transfusion vs controls. 25 Baharoglu et al 26 performed a prospective randomized controlled trial known as the PATCH (platelet transfusion vs standard care after acute stroke due to spontaneous cerebral hemorrhage associated with antiplatelet therapy). This study found that the odds of death or dependence at 3 months were higher in the platelet transfusion group than in the group that did not receive platelets (adjusted common odds ratio, 2.05, P = .011). Notably, 40 (42%) patients receiving platelets had a serious adverse event compared with 28 (29%) in the group that did not receive platelets. Finally, 23 (24%) patients receiving platelets died compared with 16 (17%) not receiving platelets. 26 Thus, this and other studies suggest that platelet transfusions may pose a much higher risk of complications and adverse outcomes than previously thought.
Similarly, a recent study by Warner et al 27 examined the effect of prophylactic platelet transfusions on the need for RBC transfusion in patients having interventional radiology (IR) procedures. They studied preprocedural platelet transfusions in patients with thrombocytopenia who were having IR procedures. A total of 2,060 patients met their criteria and had platelet counts less than 100 × 10 9 /L prior to the IR procedure, and 203 (9.9%) patients received preprocedural platelet transfusion. Using propensity-matched analyses, they did not find any differences in RBC requirements between these patients and those who did not receive platelets. However, they did find that platelet transfusion was associated with increased rates of intensive care unit (ICU) admission (odds ratio, 1.57; P = .022) and a mortality rate of 20%. 27 Thus, based on this study, preprocedure platelet transfusion appears to have minimal to no effect on bleeding as assessed through RBC transfusion and increases costs via both transfusion costs as well as ICU admission. The very high mortality rate may be due to comorbid conditions, but a degree of cause and effect remains a possibility given recent insights into platelet activation and its role in both thrombosis and inflammation. We believe that these studies together serve to highlight the likely ineffectiveness of prophylactic platelet transfusion on bleeding as well as illustrate that some of these prophylactic transfusions may potentially be harming patients.
Conclusions
Modifications of IR practice may reduce complications and save lives. For instance, in low-risk procedures, such as line placement or line removal, restricting prophylactic platelet transfusions to a platelet count of 20 or 30 × 10 9 /L (instead of the current 50 × 10 9 /L), 176 (47%) patients would have avoided platelet transfusion, as per our data. Moreover, by strictly adhering to the 50 × 10 9 /L cutoff, 34 patients would have avoided platelet transfusion. Thus, theoretically, 38 (48%) of the 79 patients with thrombotic events and/or mortality may have had improved outcomes with more restrictive transfusion guidelines. Length of hospital stay and ICU admissions due to complications, if any, which were not considered in this evaluation, might also be important. Since the 50 × 10 9 /L platelet count cutoff was arbitrarily chosen as a threshold for the prophylactic platelet transfusion in these procedures and has no evidence basis, reducing this cutoff should be considered in IR practices for better patient outcomes.
We believe that a randomized controlled clinical trial to evaluate prophylactic preprocedure platelet transfusion in patients undergoing IR and other procedures is possible. One possibility would be to select thrombocytopenic patients needing certain low-risk IR procedures such as line placement and line removal and to randomize them to either receive or not receive platelet transfusion prior to the procedure. These patients could be propensity matched to control for confounding underlying comorbidities. A randomized controlled trial to further evaluate platelet thresholds for transfusion prior to procedures or other interventions could provide necessary information that could convince physicians to withhold prophylactic platelet transfusions in many patients, thereby possibly saving numerous exposures and lives.
